2025
Serum anti-mullerian hormone levels and age among Samoan women
O’Brien G, Lambert-Messerlian G, Hawley N, Fidow U, Naseri T, Reupena M, Kershaw E, Azar M, Pangburn M, McGarvey S. Serum anti-mullerian hormone levels and age among Samoan women. Reproductive Biology And Endocrinology 2025, 23: 45. PMID: 40108611, PMCID: PMC11921511, DOI: 10.1186/s12958-025-01379-y.Peer-Reviewed Original ResearchConceptsPCOS prevalencePolycystic ovary syndromeSerum anti-Mullerian hormoneAnti-Mullerian hormoneAnti-Mullerian hormone levelsSamoan womenAssociation of anti-Mullerian hormoneContraceptive useBody mass indexSerum anti-mullerian hormone levelsEthnic minority populationsHormonal contraceptive useAMH levelsAssociated with ageFree androgen indexMinority populationsSex hormone binding globulinReproductive healthAssociated with body mass indexSerum total testosteroneAndrogen indexPrevalence of obesityRelated declineTobacco useAdult women
2024
Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).
Kalinsky K, Barlow W, Pathak H, Gralow J, Albain K, Hayes D, Lin N, Perez E, Goldstein L, Chia S, Rastogi P, Schott A, Shak S, Tripathy D, Hortobagyi G, Meric-Bernstam F, Sharma P, Pusztai L, Thompson A, Godwin A. Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER). Journal Of Clinical Oncology 2024, 42: 505-505. DOI: 10.1200/jco.2024.42.16_suppl.505.Peer-Reviewed Original ResearchInvasive disease-free survivalAnti-Mullerian hormoneFollicular stimulating hormoneAnti-Mullerian hormone levelsPremenopausal patientsRecurrence scoreChemotherapy benefitLuteinizing hormoneHormone levelsInhibin BBreast cancerBenefit of endocrine therapyNode-positive breast cancerPhase 3 randomized trialFluorescent bead-based immunoassayDisease-free survivalInvasive breast cancerNormal ovarian reserveSelf-reported menopausal statusSerum anti-Mullerian hormoneBaseline serum samplesSelection of patientsSerum hormone levelsBaseline hormone levelsUniversity of Kansas Medical CenterThe impact of ovarian endometrioma and endometriotic cystectomy on anti-Müllerian hormone, and antral follicle count: a contemporary critical appraisal of systematic reviews
Younis J, Taylor H. The impact of ovarian endometrioma and endometriotic cystectomy on anti-Müllerian hormone, and antral follicle count: a contemporary critical appraisal of systematic reviews. Frontiers In Endocrinology 2024, 15: 1397279. PMID: 38800489, PMCID: PMC11116636, DOI: 10.3389/fendo.2024.1397279.Peer-Reviewed Original ResearchAntral follicle countModerate to high-quality evidenceEndometriotic cystectomyOvarian reserveOvarian reserve measuresAnti-Mullerian hormoneLevel of evidenceOvarian endometriomaHigh-quality evidenceFollicle countImpact of ovarian endometriomasReproductive ageSystematic reviewEndometrioma per seImpact of endometriomaReserve measurementsSerum anti-Mullerian hormoneMonths post-surgeryBiomarker of choiceMeta-analysesEndometrioma diameterOvarian cystectomyComprehensive scoring systemBilateral casesUnilateral cases
2022
Anti-Mullerian Hormone Signaling: Relevance for Pathophysiology of PCOS and Implications for Novel Therapeutic Approaches to Managing Ovulatory Dysfunction of PCOS
Shapiro A, Kushnir V, Seifer D. Anti-Mullerian Hormone Signaling: Relevance for Pathophysiology of PCOS and Implications for Novel Therapeutic Approaches to Managing Ovulatory Dysfunction of PCOS. 2022, 511-525. DOI: 10.1007/978-3-030-92589-5_25.Peer-Reviewed Original ResearchPolycystic ovary syndromeAnti-Mullerian hormonePathophysiology of PCOSSerum anti-Mullerian hormoneElevated AMH levelsAvailable treatment modalitiesNovel therapeutic approachesFuture therapeutic targetsChronic anovulationOvulatory dysfunctionAMH levelsOvary syndromeOvulatory functionTreatment modalitiesNormal folliculogenesisTherapeutic approachesTherapeutic targetPatientsCritical roleAnovulationDysfunctionPathophysiologySyndromeFolliculogenesisHormone
2021
Ethnicity/Race and Age-Specific Variations of Serum AMH in Women—A Review
Kotlyar AM, Seifer DB. Ethnicity/Race and Age-Specific Variations of Serum AMH in Women—A Review. Frontiers In Endocrinology 2021, 11: 593216. PMID: 33633682, PMCID: PMC7900163, DOI: 10.3389/fendo.2020.593216.Peer-Reviewed Original Research
2014
Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS
Irani M, Minkoff H, Seifer DB, Merhi Z. Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS. The Journal Of Clinical Endocrinology & Metabolism 2014, 99: e886-e890. PMID: 24606102, DOI: 10.1210/jc.2013-4374.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsPolycystic ovary syndromeAnti-Mullerian hormoneSerum anti-Mullerian hormoneGlycation end productsVitamin DSerum sRAGED3 supplementationDeficient womenAMH concentrationsVit D3Soluble receptorDeposition of AGEsAbnormal ovarian folliculogenesisDihydroxyvitamin D3 supplementationSerum sRAGE levelsVit D3 supplementationVitamin D supplementationSerum AMH levelsVitamin D deficiencyBody mass indexD supplementationAMH levelsD deficiencySRAGE levels
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply